SBI Biotech is developing the novel therapeutic drugs in the pre-clinical stage for autoimmune diseases and cancers by targeting pDCs and B cells.

Recent News

01/13/2021

Our laboratory (Ginkgo Biomedical Research Institute) is moved to Shonan Health Innovation Park.

10/15/2019

The address of our laboratory (Ginkgo Biomedical Research Institute) has changed due to the implementation of the housing number display system.

07/17/2018

Announcement of new director.[Written in Japanese]

08/28/2017

Our headquarter office is moved to Izumi Garden Tower 15F.

10/21/2016

SBI Biotech’s Licensed product, an Anti-ILT7 antibody (MEDI7734) has achieved a Developmental Milestone in a Phase I Clinical Trial[Written in Japanese]

04/19/2016

SBI Biotech’s Licensed product, an Anti-ILT7 antibody, has IND approval to initiate a Phase Ⅰ Clinical Trial(PDF/39KB)

News Overview

 Back to top